Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. - Wikidata - awgldk - TriplyDB

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

http://www.wikidata.org/entity/Q36552780

about

Personalized treatment for advanced colorectal cancer: KRAS and beyond FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Current challenges of metastatic breast cancer.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

P2860

Q26822817-38C75F87-B055-4DE0-9C19-D0C9B9746F7D Q33712230-CC1FDD2B-7300-45B7-80D4-DA107744B853 Q36055257-772B3DB6-A74D-4DB0-9AC5-9B4582826463 Q36203560-236938B8-38CF-4DA6-8FF7-AD8B27CB12E9 Q36516784-6AF7286A-CB11-4C16-AA1B-B75F1445C29B Q36759187-AD868F9D-FA2F-485F-8FFB-7C63F5926C91 Q37471733-5C765A35-7E38-45F3-86F4-6B6107623721 Q38390840-3EED6CB8-0FB6-4A3C-8EDD-55B7ADB2F420 Q38785362-8B8E01B3-9881-4ED0-80B3-BED4AD4CC4AE Q39023377-DD7F7195-C88A-4B8B-9802-BD4F98CD55FB

P2860

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

http://www.wikidata.org/entity/Q36552780

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@ast

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@en

type

label

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@ast

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@en

prefLabel

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@ast

Fc gamma receptor IIIa polymor ...... tibodies and clinical outcome.

@en

P1433

Q36552780-A23CA2F4-DFC3-4F44-9B8A-057CEEEB1DC7

P1476

Q36552780-97CBD2F7-24D9-49F5-AFCC-A51DF5305C14

P2093

Q36552780-011E0D57-A65E-4E47-BA5B-A5DF9FEA3DCF

Q36552780-55C9C450-5ADA-4513-9BBD-876BB927C49F

Q36552780-5DFF42E6-C329-4585-978C-24B4188888ED

Q36552780-6AC95DD9-6CE6-4404-A8E0-63EEF778C9F3

Q36552780-7D0AB1E5-DE04-46C7-ABD4-32D5DBD8FC8A

Q36552780-ABAD5078-A0DF-4BBE-A94B-222D4580D2A8

Q36552780-BE922DCF-5EE1-4CF3-A2D0-E864739E310C

Q36552780-FFD5D318-DBC0-4691-825D-626FBC2B3930

P2860

Q36552780-0477DB42-54C0-49F4-BD87-AAFE57E0F8AD

Q36552780-185CA2FF-BEE6-4D86-AA2C-507BD551D5BC

Q36552780-25BEAF95-D69C-4FCE-AA73-D239ED13E109

Q36552780-3B13014B-82F9-422A-9B14-EC52BA65D93E

Q36552780-3DE79730-B11C-4509-BF9A-86FE88848A1D

Q36552780-55DF260E-7A6B-4EAC-A4AD-6A598D7C7A33

Q36552780-5695CA68-93C3-4801-A2F1-B5811DF9DA60

Q36552780-60477F12-139E-47D3-851F-568AA0886476

Q36552780-6937C3C7-FA8E-438B-926F-D03FA22DF6B1

Q36552780-8D6CCFC3-1806-4E7A-8430-5D197E2EB516

P2888

Q36552780-BBD0ECA8-78B8-484B-9219-9D73DBA0573D

P304

Q36552780-12B8CBD0-C3FC-40E5-A4B9-9B117E558289

P31

Q36552780-497625A5-6B75-4447-8D61-1864624D4AB1

P356

Q36552780-ABB961DE-769F-44D4-88C9-D08C64666846

P478

Q36552780-F2EDD248-41A4-43AD-829A-308688E412BF

P50

Q36552780-151C5E4E-D622-497B-B002-8ED5AA571680

Q36552780-160F38DB-2DE4-4055-947E-DE3C11708155

Q36552780-30DDD3DD-069E-4B7A-AA68-CA64B7EC9D11

Q36552780-66EF5727-0603-4A59-B801-B715A0188C63

Q36552780-F9FD90EC-5177-4AFA-8276-7C4C71CACB0A

P577

Q36552780-2E65147A-BB27-4103-9C59-CC4B4B6AF94A

P5875

Q36552780-C50C710B-5052-4AA0-B62E-A883D19C16D1

P6179

Q36552780-C3960709-DDE6-495A-82E2-E71D9B4BC08C

P698

Q36552780-350558D1-9884-4DAA-BEBC-CD822FF08E19

P921

Q36552780-57C2E7E6-1998-4B1A-B015-D5248C6F4FDB

P932

Q36552780-724EFE75-0F12-4AD1-92A0-168F0F486AED

P356

1479-5876-10-232

P1433

Journal of Translational Medicine

P1476

Fc gamma receptor IIIa polymor ...... ntibodies and clinical outcome

@en

P2093

Alessandro Ottaiano

http://www.w3.org/2001/XMLSchema#string

Anna Maria Trotta

http://www.w3.org/2001/XMLSchema#string

Antonino Cassata

http://www.w3.org/2001/XMLSchema#string

Carmela Romano

http://www.w3.org/2001/XMLSchema#string

Domenico Galati

http://www.w3.org/2001/XMLSchema#string

Rosa Calemma

http://www.w3.org/2001/XMLSchema#string

Serena Zanotta

http://www.w3.org/2001/XMLSchema#string

Vincenzo Rosario Iaffaioli

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

Treatment of metastatic colorectal cancer.

Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

Biological advances and clinical applications of Fc receptors for IgG.

P2888

1479-5876-10-232

P304

232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-232

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Castello

Pasquale Borrelli

Maria Napolitano

Guglielmo Nasti

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233744816

http://www.w3.org/2001/XMLSchema#string

P6179

1043528706

http://www.w3.org/2001/XMLSchema#string

P698

23171437

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3551834

http://www.w3.org/2001/XMLSchema#string